Glipizide + Metformin Hydrochloride: Brands, Price & Uses in Bangladesh

Glipizide + Metformin Hydrochloride is a fixed-dose combination oral antidiabetic indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Its use is classified by evidence strength as follows:

• Established/FDA-approved second-line use: in patients with type 2 diabetes mellitus whose hyperglycemia is not adequately controlled with diet and exercise plus either a sulfonylurea alone or metformin alone (i.e., stepping up from monotherapy that has become insufficient).
• Established/FDA-approved initial combination therapy: as initial pharmacologic therapy, together with diet and exercise, in patients whose hyperglycemia is unlikely to be controlled with monotherapy alone and who have not previously been treated with other antidiabetic agents, at the discretion of the prescriber.
• Not indicated for: type 1 diabetes mellitus or diabetic ketoacidosis, for which insulin is the required therapy.

Glipizide + Metformin Hydrochloride is not a substitute for diet, exercise, and lifestyle modification, which remain the foundation of type 2 diabetes management.

The dosage of Glipizide + Metformin Hydrochloride must be individualized by the treating physician based on current antidiabetic therapy, blood glucose control, and tolerability. It should always be taken with meals to reduce gastrointestinal upset and the risk of hypoglycemia.

Pediatric dose

Safety and efficacy of Glipizide + Metformin Hydrochloride in patients under 18 years of age have not been established; it is not recommended for pediatric use.

Renal impairment

Glipizide + Metformin Hydrochloride is contraindicated in patients with severe renal impairment (see Contraindications) because of the increased risk of metformin-associated lactic acidosis. In patients with mild to moderate renal impairment, use with caution, at a reduced dose, with regular monitoring of renal function.

Hepatic impairment

Glipizide + Metformin Hydrochloride should generally be avoided in patients with clinically significant hepatic disease, as hepatic impairment increases the risk of lactic acidosis (metformin component) and can affect glipizide metabolism.

Glipizide + Metformin Hydrochloride should be taken exactly as prescribed; do not adjust the dose without consulting a physician.

Side effects of Glipizide + Metformin Hydrochloride arise from both its glipizide and metformin components. Common side effects include:

• Gastrointestinal effects: nausea, vomiting, diarrhea, abdominal discomfort, flatulence, and a metallic taste (mainly from the metformin component, often reduced by taking with food and gradual dose titration).
• Hypoglycemia (low blood sugar): the most common adverse effect attributable to the glipizide component, more likely with irregular meals, increased physical activity, alcohol use, or in elderly/renally-impaired patients.
• Headache, dizziness, and asthenia (weakness).

Less common but serious effects include lactic acidosis (see Contraindications and Precautions) and, with long-term use, vitamin B12 deficiency. Seek prompt medical attention for symptoms of severe hypoglycemia (confusion, sweating, palpitations, loss of consciousness) or lactic acidosis (unusual muscle pain, difficulty breathing, unusual tiredness, abdominal pain, feeling cold, dizziness, slow or irregular heartbeat).